FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 7% at one stage on Monday, their biggest decline in nearly a ...

Roche's shares dropped more than 5% on Monday as the ​Swiss drugmaker failed to show that its promising breast cancer drug ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

Bishnoi Dental Care has conducted 1,000+ outreach camps in Rajasthan, screening 40,000 rural patients and improving dental ...

AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

Tamil Nadu's rising oral cancer cases call for urgent awareness, early detection, and effective tobacco cessation strategies to combat the epidemic.

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

A guide to Medicare coverage for breast cancer diagnosis and treatment, including cost differences between Original Medicare ...

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

Bristol Myers Squibb said its treatment candidate for certain blood cancers performed well in a late-stage trial.

By Sneha S K March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental drug for a rare form of blood cancer ...